Control Bionics Limited (ASX:CBL)
Australia · Delayed Price · Currency is AUD 0.0620
+0.0020 (3.33%)
Sep 18, 2026, 12:05 PM AEST
Control Bionics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 4.77 | 6.14 | 5.35 | 5.64 | 4.5 |
| 4.77 | 6.14 | 5.35 | 5.64 | 4.5 | |
Revenue Growth | -22.43% | 14.84% | -5.17% | 25.33% | 10.11% |
Cost of Revenue | 2.41 | 2.52 | 1.45 | 1.93 | 1.99 |
Gross Profit | 2.36 | 3.63 | 3.9 | 3.71 | 2.51 |
Selling, General & Admin | 7.39 | 8.03 | 7.7 | 8.45 | 8.12 |
Research & Development | 1.24 | 1.07 | 1.71 | 0.23 | 0.32 |
Other Operating Expenses | -0.63 | -0.86 | -0.99 | -0.45 | -0.35 |
Operating Expenses | 9.02 | 9.35 | 9.68 | 8.95 | 8.68 |
Operating Income | -6.66 | -5.72 | -5.78 | -5.24 | -6.18 |
Interest Expense | -0.08 | -0.11 | -0.06 | -0.02 | -0.01 |
Interest & Investment Income | 0.01 | 0.04 | 0.01 | 0.02 | 0 |
Earnings From Equity Investments | -0.05 | -0.06 | - | - | - |
Currency Exchange Gain (Loss) | 0 | -0.01 | 0 | -0 | 0.03 |
Other Non Operating Income (Expenses) | -0.28 | -0.23 | - | - | -0.03 |
EBT Excluding Unusual Items | -7.06 | -6.1 | -5.82 | -5.24 | -6.19 |
Gain (Loss) on Sale of Investments | -0.2 | - | - | - | - |
Asset Writedown | - | -0.01 | -0.09 | - | - |
Other Unusual Items | - | - | - | -0.39 | 0.09 |
Pretax Income | -7.27 | -6.11 | -5.91 | -5.63 | -6.1 |
Net Income | -7.27 | -6.11 | -5.91 | -5.63 | -6.1 |
Net Income to Common | -7.27 | -6.11 | -5.91 | -5.63 | -6.1 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 371 | 264 | 159 | 90 | 85 |
Shares Outstanding (Diluted) | 371 | 264 | 159 | 90 | 85 |
Shares Change | 40.58% | 65.68% | 76.64% | 5.80% | 36.04% |
EPS (Basic) | -0.02 | -0.02 | -0.04 | -0.06 | -0.07 |
EPS (Diluted) | -0.02 | -0.02 | -0.04 | -0.06 | -0.07 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -5.76 | -4.57 | -5.31 | -4.96 | -7.03 |
Free Cash Flow Per Share | -0.02 | -0.02 | -0.03 | -0.06 | -0.08 |
Gross Margin | 49.41% | 59.05% | 72.82% | 65.78% | 55.68% |
Operating Margin | -139.79% | -93.16% | -108.02% | -92.78% | -137.19% |
Profit Margin | -152.42% | -99.41% | -110.52% | -99.80% | -135.53% |
Free Cash Flow Margin | -120.81% | -74.40% | -99.24% | -87.84% | -156.26% |
EBITDA | -6 | -4.91 | -5.06 | -4.87 | -5.76 |
EBITDA Margin | -125.86% | -79.85% | -94.50% | -86.31% | -127.93% |
D&A For EBITDA | 0.66 | 0.82 | 0.72 | 0.37 | 0.42 |
EBIT | -6.66 | -5.72 | -5.78 | -5.24 | -6.18 |
EBIT Margin | -139.79% | -93.16% | -108.02% | -92.78% | -137.19% |
Revenue as Reported | - | - | - | 6.11 | 4.94 |